Hunter Perkins Capital Management LLC Makes New $5.38 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Hunter Perkins Capital Management LLC purchased a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 8,482 shares of the biopharmaceutical company's stock, valued at approximately $5,380,000. Regeneron Pharmaceuticals accounts for 1.2% of Hunter Perkins Capital Management LLC's holdings, making the stock its 26th largest position.

A number of other large investors also recently modified their holdings of REGN. Brighton Jones LLC raised its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after buying an additional 686 shares during the last quarter. Sigma Planning Corp increased its stake in Regeneron Pharmaceuticals by 91.2% during the fourth quarter. Sigma Planning Corp now owns 782 shares of the biopharmaceutical company's stock valued at $557,000 after acquiring an additional 373 shares during the period. IFP Advisors Inc increased its stake in Regeneron Pharmaceuticals by 17.2% during the fourth quarter. IFP Advisors Inc now owns 368 shares of the biopharmaceutical company's stock valued at $262,000 after acquiring an additional 54 shares during the period. Lake Street Advisors Group LLC raised its holdings in Regeneron Pharmaceuticals by 9.3% in the 4th quarter. Lake Street Advisors Group LLC now owns 779 shares of the biopharmaceutical company's stock valued at $555,000 after acquiring an additional 66 shares in the last quarter. Finally, National Pension Service raised its holdings in Regeneron Pharmaceuticals by 4.0% in the 4th quarter. National Pension Service now owns 232,450 shares of the biopharmaceutical company's stock valued at $165,581,000 after acquiring an additional 8,833 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN remained flat at $521.00 during trading hours on Friday. 1,607,735 shares of the company traded hands, compared to its average volume of 897,423. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm has a market cap of $56.25 billion, a price-to-earnings ratio of 13.26, a P/E/G ratio of 1.91 and a beta of 0.31. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The stock has a fifty day moving average of $555.02 and a two-hundred day moving average of $634.70.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same period last year, the company earned $9.55 EPS. The business's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.68%. The ex-dividend date of this dividend was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.96%.

Analyst Ratings Changes

REGN has been the topic of a number of research reports. Royal Bank Of Canada cut Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price objective on the stock. in a research report on Friday, May 30th. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating on the stock in a report on Wednesday, April 30th. Robert W. Baird dropped their price objective on shares of Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating for the company in a research note on Friday, April 25th. Wells Fargo & Company lowered shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their target price for the company from $700.00 to $580.00 in a research report on Friday, May 30th. Finally, Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating on the stock in a research note on Monday, June 2nd. One research analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $822.58.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.